

Antwerp, 7 August 2015, 17h00 CET

Gimv's medtech portfolio company JenaValve raises USD 26.5 million

JenaValve (www.jenavalve.com), today announced that it raised USD 26.5 million financing from an international investor syndicate including Gimv. This is one of the largest financing rounds for a medtech company in Europe.

JenaValve, with operations in Munich (GER), Leeds (UK) and Irvine, California (US), develops, manufactures and markets transcatheter aortic valve repair (TAVR) systems. The proceeds from the financing will be used to enable clinical studies and commercial development of innovative transcatheter aortic valve repair (TAVR) systems and strengthen the company's position in this market.

Gimv was lead investor in the previous Series B financing round and confirms with this follow-on investment its belief in the further growth of the company.

For more information on this transaction we refer to the press release of JenaValve in attach.

ABOUT GIMV

Gimv is a European investment company with over three decades experience in private equity and venture capital. The company is listed on NYSE Euronext Brussels and currently manages around 1.8 billion EUR (including investment partnerships) of investments in 50 portfolio companies.

As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial and innovative companies with high-growth potential and supports them in their transformation into market leaders. Gimv's four investment platforms are: Consumer 2020, Health & Care, Smart Industries and Sustainable Cities. Each of these platforms works with a skilled and dedicated team across Gimv's home markets of the Benelux, France and Germany and can count on an extended international network of experts.

More information on Gimv can be found on www.gimv.com.

For further information please contact:

Frank De Leenheer, Investor Relations & Corporate Communications Manager

T +32 3 290 22 18 – frank.deleenheer@gimv.com

Patrick Van Beneden, Gimv Health & Care

T +32 3 290 21 36 – patrick.vanbeneden@gimv.com



JENAVALVE RECEIVES \$26.5 MILLION FINANCING

Proceeds to Enable Clinical Studies and Commercial Development of Innovative TAVR Systems Targeting Broad Patient Population

Irvine, Calif. – August 7, 2015 – [JenaValve Technology](#), Inc., a developer, manufacturer and marketer of next-generation transcatheter aortic valve repair (TAVR) systems for the treatment of aortic valve disease, today announced the successful completion of a \$26.5 million Series C expansion round of financing. Proceeds from the financing will be used to support the Company's further growth in the global TAVR market.

“As we advance our science and products to treat a broad range of patients with aortic disease, this round of funding will enable us to execute key clinical studies required to gain European regulatory approval and complete a US feasibility study for our new aortic valve and transfemoral delivery system,” said Victoria E. Carr-Brendel, Ph.D., chief executive officer of JenaValve. “This financing is testament to the strength of our technology, the support of our investors and our promise to evolve into an effective competitor in this rapidly growing market.”

The financing round was co-led by RMM (Rudi Mariën) and Valiance and included participation from the existing syndicate of Atlas Venture, Edmond de Rothschild Investment Partners, Gimv, Legend Capital, NeoMed Management and VI Partners.

“To compete in TAVR requires serious financial backing and JenaValve is fortunate to have the continued support of this top-tier investor syndicate as we execute on the work required to launch our new TAVR system worldwide,” said Jan Keltjens, Chairman of the Board of Directors of JenaValve. “This financing provides the Company with the resources to deliver truly differentiated solutions for patients in need.”

About JenaValve

JenaValve Technology, with operating locations in Munich, Germany and Irvine, California, develops, manufactures and markets transcatheter aortic valve repair (TAVR) systems to treat patients suffering from aortic valve disease. The Company's Transapical TAVR system, consisting of the JenaValve valve system plus Cathlete PLUS delivery system, has CE Mark approval for aortic valve stenosis and for the unique indication to treat patients suffering from aortic valve insufficiency. JenaValve currently markets this product in Europe and other selected markets worldwide. JenaValve is backed by world-class U.S., European and Asian investors, including Atlas Venture, Edmond de Rothschild Investment Partners, Gimv (a Euronext-listed investment company - ticker: GIMB), Legend Capital, NeoMed Management, Omega Funds, RMM, Sunstone Capital, Valiance and VI Partners.

Additional information is available at www.jenavalve.com.

Media Contact:

Katie Engleman

Pure Communications +1-910-509-3977

katie@purecommunicationsinc.com

Investor Contact:

Matt Clawson

Pure Communications, Inc. +1-949-370-8500

matt@purecommunicationsinc.com